Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

The C-X-C chemokine receptor type 4 (CXCR4)–stromal cell-derived factor-1α (SDF-1α) axis regulates function and trafficking of immune cells and the tumour microenvironment. CXCR4 antagonists have been shown to enhance the activity of different anticancer treatments in preclinical models. We assessed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2018-06, Vol.19 (6), p.812-824
Hauptverfasser:	Pernas, Sonia, Martin, Miguel, Kaufman, Peter A, Gil-Martin, Marta, Gomez Pardo, Patricia, Lopez-Tarruella, Sara, Manso, Luis, Ciruelos, Eva, Perez-Fidalgo, Jose Alejandro, Hernando, Cristina, Ademuyiwa, Foluso O, Weilbaecher, Katherine, Mayer, Ingrid, Pluard, Timothy J, Martinez Garcia, Maria, Vahdat, Linda, Perez-Garcia, Jose, Wach, Achim, Barker, Debra, Fung, Samson, Romagnoli, Barbara, Cortes, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	Alopecia Antagonists Breast cancer Cancer therapies Chemotherapy Clinical trials Constipation CXCR4 protein Cytotoxicity Endocrine therapy ErbB-2 protein Fatigue Immunosuppressive agents Intravenous administration Leukemia Medical prognosis Metastases Metastasis Nausea Neutropenia Pain Patients Pharmacokinetics Pneumonia Safety Septic shock Studies Toxicity Tumor microenvironment Tumors Urinary tract
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!